Figures computed from official regulatory filings — .
Analysttarget 13 USD (+1624900%) · consensus 4.5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 0% · institutions 0.04% · short 12.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Sorrento Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
70 buys54 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Ji Henrytrack record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) |
| Ji Henrytrack record | Other | $15.6K | Unusual size | SEC |
| Janda Kim | Sell | $31.3K | SEC |
| Ji Henrytrack record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ji Henrytrack record | Other | $1.1K | SEC |
| Ji Henrytrack record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ji Henrytrack record | Other | $1.7K | Unusual size | SEC |
| Ji Henrytrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ji Henrytrack record | BuyD (derivative) | $30.9K | SEC |
| Ji Henrytrack record | BuyD (derivative) | $5.4K | SEC |
| Ji Henrytrack record | Buy | $179.6K | conv 21 | SEC |
| Ji Henrytrack record | Buy | $108.9K | conv 17 | SEC |
| Ji Henrytrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ji Henrytrack record | SellD (derivative) | $69.9K | SEC |
| Ji Henrytrack record | Buy | $70.3K | conv 15 | SEC |
| Ji Henrytrack record | BuyD (derivative) | $30.7K | SEC |
| Ji Henrytrack record | Buy | $45.8K | conv 17 | SEC |
| Ji Henrytrack record | Buy | $14K | conv 41First in 12mo | SEC |
| Reilly Tammy | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CZEREPAK ELIZABETH | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Janda Kim | Exercise | $12K | SEC |
| Janda Kim | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Janda Kim | Sell | $17.6K | SEC |
| CZEREPAK ELIZABETH | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ji Henrytrack record | Exercise | $40K | SEC |